LBX(SH:603883) Shang Hai Zheng Quan Bao·2025-12-03 19:55Core Viewpoint - The company held a Q3 earnings presentation on December 2, 2025, to provide insights into its performance and address investor inquiries regarding various operational aspects and market conditions [1][2]. Group 1: Earnings Presentation Overview - The earnings presentation was conducted via a video live stream and included participation from key executives, allowing for direct communication with investors [2]. - The company reported a cash dividend of 0.14 yuan per share, totaling 1.06 billion yuan distributed to shareholders [5]. Group 2: Supply and Market Conditions - The company ensured a stable supply of four categories of medicines in response to increased health demands due to a flu outbreak, with sales showing a month-on-month increase since November [3]. - The industry is experiencing accelerated consolidation, with a net decrease of 3,166 and 4,002 pharmacies in the first and second quarters of 2025, respectively, leading to a total of 695,000 pharmacies [3][4]. Group 3: Strategic Initiatives - The company is focusing on enhancing its online business, achieving a 28% year-on-year growth in online sales for the first three quarters of 2025, and plans to implement strategies for quality improvement and operational efficiency [6]. - The company has initiated a dual-line transformation in its stores, aiming to shift staff roles from sales to health advisory positions, enhancing customer experience [8]. Group 4: Financial Performance and Future Outlook - The overall gross margin decreased in the first three quarters of 2025, primarily due to an increase in the sales proportion of lower-margin products, while core business segments maintained stable or improved margins [9]. - The company is implementing measures to optimize its sales structure and improve gross margins, including refining product offerings and enhancing procurement and logistics efficiency [9].